Email this article 
Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases
- Authors: Dashyan G.A.1,2, Semiglazov V.F.1,2, Krivorot’ko P.V.1,2, Semiglazova T.Y.1,2, Topuzov E.E.3,4, Paltuev R.M.1,2, Zernov K.Y.1,2, Apollonova V.S.1,2, Ereshchenko S.S.1,2, Petrova A.V.1,2, Zhil’tsova E.K.1,2, Ivanova O.A.1,2
-
Affiliations:
- N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia
- 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, Russia
- I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia
- 41 Kirochnaya St., Saint Petersburg, 191015, Russia
- Issue: Vol 12, No 1 (2016)
- Pages: 46-51
- Section: MAMMOLOGY. TREATMENT
- Published: 06.06.2016
- URL: https://ojrs.abvpress.ru/ojrs/article/view/475
- DOI: https://doi.org/10.17650/1994-4098-2016-12-1-46-51
- ID: 475
Cite item
Full Text
Abstract
Brain metastases are detectable in 25–35 % of patients with progressive HER-2-positve breast cancer. Even after spreading metastases into the brain, chemotherapy in combination with anti-HER- 2 therapy improves survival due to better control of the systemic disease. The paper presents the results of investigations substantiating the use of anti-HER-2 targeting agents, as well as the innovative agent T-DM1 to treat brain metastases.
About the authors
G. A. Dashyan
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, Russia
Author for correspondence.
Email: dgarik@mail.ru
Russian Federation
V. F. Semiglazov
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Federation
P. V. Krivorot’ko
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Federation
T. Yu. Semiglazova
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Federation
E. E. Topuzov
I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia; 41 Kirochnaya St., Saint Petersburg, 191015, RussiaRussian Federation
R. M. Paltuev
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Federation
K. Yu. Zernov
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Federation
V. S. Apollonova
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Federation
S. S. Ereshchenko
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Federation
A. V. Petrova
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Federation
E. K. Zhil’tsova
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Federation
O. A. Ivanova
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Federation
References
Supplementary files
